{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:11:36Z","timestamp":1770743496877,"version":"3.49.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.hoc.2017.04.009","type":"journal-article","created":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T01:01:21Z","timestamp":1498870881000},"page":"643-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis"],"prefix":"10.1016","volume":"31","author":[{"given":"Jason","family":"Gotlib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2017.04.009_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib2","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.hoc.2017.04.009_bib3","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2017.04.009_bib4","first-page":"9","article-title":"Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate","volume":"3","author":"Schaller","year":"2001","journal-title":"MedGenMed"},{"key":"10.1016\/j.hoc.2017.04.009_bib5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2017.04.009_bib6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(02)00046-2","article-title":"Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate","volume":"26","author":"Ault","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2017.04.009_bib7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A\u00a0tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2017.04.009_bib8","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1073\/pnas.0932698100","article-title":"Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome","volume":"100","author":"Griffin","year":"2003","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2017.04.009_bib9","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.009_bib11","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib12","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2017.04.009_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2017.04.009_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hon.919","article-title":"Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript\u2013results of Polish multicentre study","volume":"28","author":"Helbig","year":"2010","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hoc.2017.04.009_bib15","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/leu.2012.162","article-title":"Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome","volume":"26","author":"Pardanani","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.hoc.2017.04.009_bib16","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","article-title":"The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases","volume":"92","author":"Legrand","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.hoc.2017.04.009_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","article-title":"A\u00a0single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients","volume":"141","author":"Helbig","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib18","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","article-title":"Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing","volume":"110","author":"Klion","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2017.04.009_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajh.23588","article-title":"Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome","volume":"89","author":"Helbig","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2403600","article-title":"Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFRalpha-positive chronic myeloproliferative disease with prominent eosinophilia","volume":"19","author":"Von Bubnoff","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.009_bib22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2141.2006.06221.x","article-title":"Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy","volume":"134","author":"Ohnishi","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","article-title":"FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib","volume":"23","author":"Lierman","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.009_bib24","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib25","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1182\/blood-2006-01-0285","article-title":"The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)","volume":"107","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/leu.2011.181","article-title":"Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation","volume":"26","author":"Metzgeroth","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.009_bib27","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.hoc.2017.04.009_bib29","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/leu.2012.8","article-title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases","volume":"26","author":"Lierman","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2017.04.009_bib30","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2013.12.007","article-title":"Identification of ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA","volume":"42","author":"Sadovnik","year":"2014","journal-title":"Exp Hematol"},{"issue":"8","key":"10.1016\/j.hoc.2017.04.009_bib31","doi-asserted-by":"crossref","first-page":"e73059","DOI":"10.1371\/journal.pone.0073059","article-title":"The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFR\u03b1","volume":"29","author":"Shen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2017.04.009_bib32","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaci.2007.11.027","article-title":"Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia","volume":"121","author":"Simon","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.hoc.2017.04.009_bib33","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/leu.2015.70","article-title":"F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance","volume":"29","author":"Gorantla","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2017.04.009_bib34","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/ajh.24196","article-title":"World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management","volume":"90","author":"Gotlib","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","article-title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders","volume":"109","author":"Cross","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib36","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib37","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2013.129","article-title":"Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid\/lymphoid neoplasms with PDGFR rearrangements in blast phase","volume":"27","author":"Metzgeroth","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.009_bib38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ng0198-84","article-title":"FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia\/lymphoma syndrome","volume":"18","author":"Xiao","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2017.04.009_bib39","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1182\/blood.V95.5.1788.005k15_1788_1796","article-title":"FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33)","volume":"95","author":"Guasch","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib40","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V93.4.1381","article-title":"The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1","volume":"93","author":"Popovici","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib41","series-title":"World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues","first-page":"68","article-title":"Myeloid and lymphoid neoplasms with\u00a0eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1","author":"Bain","year":"2008"},{"key":"10.1016\/j.hoc.2017.04.009_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ijlh.12057","article-title":"Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review","volume":"35","author":"Savage","year":"2013","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib43","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1073\/pnas.0404438101","article-title":"PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2017.04.009_bib44","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2012.066407","article-title":"Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome","volume":"98","author":"Chase","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2017.04.009_bib45","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2015.136","article-title":"Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed phenotype acute leukemia","volume":"30","author":"Khodadoust","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.009_bib46","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.V126.23.2812.2812","article-title":"Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes","volume":"126","author":"Kreil","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2017.04.009_bib47","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2017.04.009_bib48","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2017.04.009_bib49","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2017.04.009_bib50","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2017.04.009_bib51","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ajh.24075","article-title":"KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance","volume":"90","author":"Schwaab","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib52","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2016.73","article-title":"Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.009_bib53","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1002\/eji.1830271256","article-title":"Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils","volume":"27","author":"Simon","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.hoc.2017.04.009_bib54","doi-asserted-by":"crossref","first-page":"e34912","DOI":"10.1371\/journal.pone.0034912","article-title":"Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2017.04.009_bib55","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2017.04.009_bib56","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.leu.2403879","article-title":"PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation","volume":"19","author":"Murati","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.009_bib57","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1038\/sj.onc.1208850","article-title":"The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene","volume":"24","author":"Bousquet","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2017.04.009_bib58","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cancergen.2016.03.002","article-title":"BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia","volume":"209","author":"He","year":"2016","journal-title":"Cancer Genet"},{"key":"10.1016\/j.hoc.2017.04.009_bib60","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/ejh.12752","article-title":"Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript","volume":"97","author":"Duployez","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib61","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bjh.12963","article-title":"Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?","volume":"166","author":"Bain","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib62","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1182\/blood-2012-06-433821","article-title":"Ruxolitinib inhibits transforming JAK2 fusion proteins in\u00a0vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)\/PCM1-JAK2-positive chronic eosinophilic leukemia","volume":"120","author":"Lierman","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib63","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1200\/JCO.2012.46.4370","article-title":"Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene","volume":"31","author":"Rumi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2017.04.009_bib64","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","article-title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene","volume":"94","author":"Rumi","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib65","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","article-title":"Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes","volume":"94","author":"Schwaab","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib66","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.leu.2404266","article-title":"FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation","volume":"20","author":"Vu","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.009_bib67","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12308-014-0203-6","article-title":"ETV6\/FLT3 fusion in a mixed-phenotype acute leukemia arising in lymph nodes in a patient with myeloproliferative neoplasm with eosinophilia","volume":"7","author":"Hosseini","year":"2014","journal-title":"J\u00a0Hematopathol"},{"issue":"8","key":"10.1016\/j.hoc.2017.04.009_bib68","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"116","author":"Walz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib69","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/leu.2014.168","article-title":"ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant","volume":"28","author":"Falchi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.009_bib70","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00277-013-1843-9","article-title":"Successful allogeneic stem cell\u00a0transplantation with long-term remission of ETV6\/FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia","volume":"93","author":"Chonabayashi","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib71","series-title":"WHO classification of tumors of hematopoietic and lymphoid tissues","first-page":"54","article-title":"Mastocytosis","author":"Horny","year":"2008"},{"issue":"23","key":"10.1016\/j.hoc.2017.04.009_bib72","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2017.04.009_bib73","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2017.04.009_bib74","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000048186","article-title":"Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis","volume":"127","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/j.hoc.2017.04.009_bib75","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ajh.23931","article-title":"Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management","volume":"90","author":"Pardanani","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib76","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J\u00a0Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2017.04.009_bib77","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2017.04.009_bib78","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib79","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","article-title":"Dasatinib therapy for systemic mastocytosis: four cases","volume":"80","author":"Purtill","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib80","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2017.04.009_bib81","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00432-015-1988-0","article-title":"Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study","volume":"141","author":"Hochhaus","year":"2015","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.hoc.2017.04.009_bib82","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib83","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib84","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2017.04.009_bib85","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2017.04.009_bib86","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A\u00a0novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib87","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2017.04.009_bib88","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A\u00a0novel K509I mutation of KIT identified in familial mastocytosis\u2014in\u00a0vitro and in\u00a0vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2017.04.009_bib89","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2008-03-147785","article-title":"Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation","volume":"112","author":"Hoffmann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib90","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-0609.2011.01598.x","article-title":"A\u00a0case of mast cell leukemia with exon 9 KIT mutation and good response to imatinib","volume":"86","author":"Mital","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib91","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.hoc.2017.04.009_bib92","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.critrevonc.2013.12.011","article-title":"Masitinib (AB1010), from canine tumor model to human clinical development: where are we?","volume":"91","author":"Marech","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib93","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2017.04.009_bib94","doi-asserted-by":"crossref","first-page":"e26375","DOI":"10.1371\/journal.pone.0026375","article-title":"Depression in patients with mastocytosis: prevalence, features an effects of masitinib therapy","volume":"6","author":"Moura","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2017.04.009_bib95","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of\u00a0severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2017.04.009_bib96","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/blood.V116.21.316.316","article-title":"KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial","volume":"116","author":"Gotlib","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib97","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.hoc.2017.04.009_bib98","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1182\/blood.V124.21.3217.3217","article-title":"First selective KIT D816V inhibitor for patients with systemic mastocytosis","volume":"124","author":"Evans","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.009_bib99","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/blood.V128.22.477.477","article-title":"Preliminary safety and clinical activity in a phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (SM)","volume":"126","author":"Drummond","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2017.04.009_bib100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2353\/jmoldx.2008.070061","article-title":"Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a clonal hematological non-mast cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F","volume":"10","author":"Sotlar","year":"2008","journal-title":"J\u00a0Mol Diagn"},{"issue":"14","key":"10.1016\/j.hoc.2017.04.009_bib101","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"3\u20134","key":"10.1016\/j.hoc.2017.04.009_bib102","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000203882","article-title":"JAK2 is constitutively associated with c-Kit and is phosphorylated in response to stem cell factor","volume":"95","author":"Linnekin","year":"1996","journal-title":"Acta Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2017.04.009_bib103","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1182\/blood.V87.9.3688.bloodjournal8793688","article-title":"JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor","volume":"87","author":"Weiler","year":"1996","journal-title":"Blood"},{"issue":"50","key":"10.1016\/j.hoc.2017.04.009_bib104","doi-asserted-by":"crossref","first-page":"31680","DOI":"10.1016\/S0021-9258(18)31749-6","article-title":"Convergence of signaling by interleukin-3, granulocyte-macrophage colony-stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase","volume":"269","author":"Brizzi","year":"1994","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.hoc.2017.04.009_bib105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.exphem.2003.11.006","article-title":"JAK2 contributes to the intrinsic capacity of primary hematopoietic cells to respond to stem cell factor","volume":"32","author":"Radosevic","year":"2004","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2017.04.009_bib106","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.bbrc.2009.10.050","article-title":"Role of Janus kinase-2 in IgE receptor-mediated leukotriene C4 production by mast cells","volume":"390","author":"Sur","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.hoc.2017.04.009_bib107","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/leu.2010.109","article-title":"Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells","volume":"24","author":"Lasho","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.009_bib108","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40364-016-0056-5","article-title":"Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis","volume":"4","author":"Yacoub","year":"2016","journal-title":"Biomark Res"},{"issue":"2","key":"10.1016\/j.hoc.2017.04.009_bib109","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bjh.13951","article-title":"Beneficial effects of JAK inhibitor therapy in systemic mastocytosis","volume":"176","author":"Dowse","year":"2017","journal-title":"Br J Haematol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858817300667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858817300667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:05:11Z","timestamp":1760184311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858817300667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0889858817300667"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2017.04.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2017.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}